{
  "parties": [
    "NOVO INTEGRATED SCIENCES INC. (\"NVOS\")",
    "HARVEST GOLD FARMS INC"
  ],
  "effective_date": null,
  "governing_law": null,
  "payment_terms": null,
  "termination_clause": {
    "text": "termination. 9.3 To remunerate HGF on the basis of thirty percent (30%) of net Company income basis on an annual basis commencing 12 months after the first full 12-month revenue period. 9.4 To purchase product from the Company at a price of cost plus five percent (5%). 9.5 To issue two (2) million NVOS common stock upon successful target of twenty-five million dollars ($25M) of net profit achieved by the Company each fiscal year. NVOS common stock will be delivered to HGF via Novo Healthnet Limited (\"NHL\") exchangeable preferred shares. All parties understand NVOS is a U.S. reporting publicly traded corporation and that any NVOS common shares issued, from exchanging the NHL exchangeable preferred shares, will be provided under the guiding U.S. rules and regulations. Furthermore, all parties understan",
    "start": 11405,
    "end": 12216
  },
  "_doc_id": "NOVOINTEGRATEDSCIENCES,INC_12_23_2019-EX-10.1-JOINT VENTURE AGREEMENT.txt",
  "_char_count": 21955,
  "payment_net_days": null,
  "_issues": [
    {
      "field": "effective_date",
      "type": "MISSING",
      "detail": "Required field 'effective_date' is missing"
    },
    {
      "field": "governing_law",
      "type": "MISSING",
      "detail": "Required field 'governing_law' is missing"
    },
    {
      "field": "payment_terms",
      "type": "MISSING",
      "detail": "Required field 'payment_terms' is missing"
    }
  ]
}